Analysts Set Expectations for ADCT FY2026 Earnings

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of ADC Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings of ($2.10) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share.

Other research analysts have also issued research reports about the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Monday, March 31st. Guggenheim upped their price target on ADC Therapeutics from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Friday. Finally, Stephens upped their price target on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $8.50.

ADC Therapeutics Price Performance

ADCT traded down $0.06 during midday trading on Wednesday, reaching $3.62. 829,699 shares of the company's stock traded hands, compared to its average volume of 616,396. The firm has a fifty day moving average of $2.00 and a two-hundred day moving average of $1.88. The stock has a market capitalization of $358.53 million, a price-to-earnings ratio of -1.51 and a beta of 1.96. ADC Therapeutics has a 52 week low of $1.05 and a 52 week high of $4.13.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.02. The business had revenue of $23.03 million for the quarter, compared to the consensus estimate of $17.71 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cerity Partners LLC purchased a new position in shares of ADC Therapeutics during the 1st quarter worth approximately $25,000. Kazazian Asset Management LLC purchased a new position in shares of ADC Therapeutics during the 4th quarter worth approximately $26,000. Atria Wealth Solutions Inc. purchased a new position in shares of ADC Therapeutics during the 1st quarter worth approximately $28,000. Two Sigma Securities LLC purchased a new position in shares of ADC Therapeutics during the 4th quarter worth approximately $30,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of ADC Therapeutics by 122.6% during the 4th quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company's stock worth $33,000 after acquiring an additional 9,248 shares during the period. Hedge funds and other institutional investors own 41.10% of the company's stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.